0000899243-23-012347.txt : 20230505
0000899243-23-012347.hdr.sgml : 20230505
20230505161011
ACCESSION NUMBER: 0000899243-23-012347
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230428
FILED AS OF DATE: 20230505
DATE AS OF CHANGE: 20230505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aromando Andrew
CENTRAL INDEX KEY: 0001976455
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40505
FILM NUMBER: 23893902
MAIL ADDRESS:
STREET 1: C/O AMBRX BIOPHARMA INC.
STREET 2: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ambrx Biopharma Inc.
CENTRAL INDEX KEY: 0001836056
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 571147346
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 875-2400
MAIL ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-28
0
0001836056
Ambrx Biopharma Inc.
AMAM
0001976455
Aromando Andrew
C/O AMBRX BIOPHARMA INC.,
10975 TORREY PINES ROAD
LA JOLLA
CA
92037
0
1
0
0
Chief Operating Officer
0
Stock Option (right to buy)
1.38
2023-04-28
4
A
0
2600000
0.00
A
2033-04-28
Ordinary Shares
2600000
2600000
D
The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer.
Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date.
The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.
/s/ Sonja Nelson, Attorney-in-Fact for Andrew Aromando
2023-05-05